"10.1371_journal.pone.0060229","plos one","2013-04-02T00:00:00Z","Helge RÃ¦der; Mette Vesterhus; Abdelfattah El Ouaamari; Joao A Paulo; Fiona E McAllister; Chong Wee Liew; Jiang Hu; Dan Kawamori; Anders Molven; Steven P Gygi; PÃ¥l R NjÃ¸lstad; C Ronald Kahn; Rohit N Kulkarni","Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States of America; KG Jebsen Center for Diabetes Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Pediatrics, Haukeland University Hospital, Bergen, Norway; Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America; The Gade Institute, University of Bergen, Bergen, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway; Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: HR MV PRN CRK RNK. Performed the experiments: HR MV AEO JAP FEM JH DK PRN. Analyzed the data: HR MV AEO JAP FEM CWL JH DK AM SPG PRN CRK RNK. Wrote the paper: HR MV AEO JAP FEM CWL JH DK AM SPG PRN CRK RNK.","The authors declare the commercial funder Innovest: Innovest is a company that is owned by the University of Bergen and Haukeland University Hospital, both in Bergen, Norway. Innovest is managing funds and grants for researchers employed by the two institutions. Innovest also manages some strategic funds from the two institutions, and PRN receives 100000 US$ yearly from these. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials.","2013","04","Helge RÃ¦der","HRÃ",13,TRUE,5,8,13,13,TRUE,TRUE,FALSE,0,NA,FALSE
